万孚生物(300482) - 2021 Q3 - 季度财报

Revenue and Profit - Revenue for Q3 2021 reached ¥650,897,355.23, an increase of 14.91% year-over-year[3] - Net profit attributable to shareholders was ¥71,567,214.22, a decrease of 38.80% compared to the same period last year[3] - Net profit excluding non-recurring gains and losses was ¥52,221,281.83, down 55.12% year-over-year[3] - Total operating revenue for the current period reached ¥2,507,113,200.58, an increase of 15.4% compared to ¥2,173,091,511.35 in the previous period[25] - Net profit for the current period was ¥626,568,566.26, representing a 10.4% increase from ¥567,334,882.63 in the previous period[28] Cash Flow - Operating cash flow for the year-to-date period was ¥270,188,527.22, a decline of 62.02%[3] - Cash flow from operating activities totaled ¥2,405,182,078.61, a decrease from ¥2,426,545,467.41 in the previous period[32] - The net cash flow from operating activities was 270,188,527.22, a decrease of 62% compared to 711,362,137.81 in the previous period[35] - Cash inflow from financing activities was 72,987,212.53, down 90% from 699,619,126.95 in the previous period[35] - The net cash flow from financing activities was -272,201,846.67, compared to a positive flow of 582,010,015.36 in the previous period[35] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,681,614,415.86, reflecting an increase of 8.72% from the previous year[3] - The company's current assets totaled RMB 2,502,089,265.54 as of September 30, 2021, compared to RMB 2,270,293,935.69 at the end of 2020, indicating an increase of about 10.2%[18] - The company's total liabilities decreased to RMB 1,229,802,741.77 from RMB 1,312,467,101.44, showing a reduction of about 6.3%[21] - Total liabilities amounted to approximately 1.31 billion, a slight decrease from 1.32 billion in the previous period[45] - Non-current liabilities totaled approximately 519 million, down from 530 million[45] Shareholder Equity - Shareholders' equity attributable to the parent company was ¥3,312,927,356.29, up 16.56% from the end of the previous year[5] - The equity attributable to the owners of the parent company increased to RMB 3,312,927,356.29 from RMB 2,842,304,409.45, representing a growth of approximately 16.5%[24] - Total equity reached approximately 2.99 billion, remaining stable compared to the previous period[45] Investments and Expenses - Research and development expenses rose to ¥276,627,339.80, a 27.2% increase compared to ¥217,498,750.11 in the previous period[25] - The company reported an investment income of ¥48,014,903.49, compared to a loss of ¥1,902,599.35 in the previous period[25] - The company reported a cash outflow of 5,148,036,386.14 from investment activities, an increase from 4,390,949,769.43 in the previous period[35] Inventory and Receivables - Accounts receivable increased by 97.69% to ¥532,414,436.00, corresponding to higher revenue[6] - The inventory increased to RMB 467,099,475.33 from RMB 376,664,965.00, reflecting a growth of approximately 24%[18] Stock and Shares - The company plans to unlock 98,280 shares of restricted stock as part of its incentive plan, with a total of 103,428 shares to be repurchased and canceled[14] - The total number of restricted shares at the end of the period was 2,373,293, down from 2,575,001 at the beginning of the period, indicating a decrease of about 7.8%[14] Other Financial Metrics - Basic and diluted earnings per share were both ¥1.28 for the current period[30] - Other comprehensive income after tax was reported at -¥468,897.25, an improvement from -¥1,661,821.64 in the previous period[28] - The company received tax refunds amounting to ¥12,149,117.65, compared to ¥2,862,854.08 in the previous period[32]